|By Marketwired .||
|June 20, 2014 08:45 AM EDT||
RICHLAND, WA -- (Marketwired) -- 06/20/14 -- IsoRay, Inc. (NYSE MKT: ISR) (http://www.isoray.com/), announced today that it has entered into two (2) international distribution agreements: the first with MedikorPharma-Ural LLC for the Russian market and the other with Surgicorp SRL for the Peruvian market. IsoRay is a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer, head and neck cancer, prostate cancer and gynecologic ("gyn") cancer.
MedikorPharma and Surgicorp SRL both now have the right to distribute all of IsoRay's products within their countries. Together with IsoRay's other international distributors, MedikorPharma and Surgicorp SRL are expected to support IsoRay's long term goals by obtaining increased recognition in the world marketplace for Cesium-131. IsoRay's Cesium-131 products utilize the uniqueness of IsoRay's Cesium-131 isotope to attack cancers in the prostate and other body sites, such as brain cancer, head and neck cancer, lung cancer and gynecological cancers, while providing patients with a better quality of life than many competing treatments. IsoRay's continued success story will be accelerated as more physicians and surgeons in the US and internationally are made aware of the power of Cesium-131 through published studies reporting positive patient outcomes from treatment with IsoRay products.
IsoRay Chairman and CEO Dwight Babcock commented, "We are very optimistic about achieving growth in adoption of our growing array of new products and look to the international market to contribute in the future as IsoRay's products receive the additional foreign regulatory approvals and licenses needed for the sale of our products in additional countries. All of our products, except our just announced liquid Cesium-131 (Cesitrex®) for use in our GliaSite® Radiation Therapy System, currently carry the CE Mark, making them eligible to be sold in 31 European nations. Physicians and institutions throughout the US are continuing to report outstanding results in the use of our Cesium-131 seeds for brain cancer, head and neck cancer, prostate cancer, lung cancer and gynecological cancers. Given this growing acceptance and interest, we remain committed to our strategic national and international marketing objectives and believe this will contribute to our long term success."
The Company is actively bringing new brachytherapy applications to market, providing new solutions to leading physicians throughout the world. The Company's continued investment in research and development focusing on Cesium-131's efficacy for treatment of various cancers located throughout the body is expected to have a direct impact on its overall growth with an expanding array of non-prostate cancer treatments. In addition, the recent reorganization and increase in the size and quality of IsoRay's sales organization in the US market has created the means to contact more facilities than ever before with the Company's new and novel treatment alternatives.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which is expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on [email protected]
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including: the advantages of our products and their delivery systems, whether sales of our products both in the U.S. and internationally will continue at historic levels, decrease or increase, whether the use of our products will increase or continue, whether future studies of treatment of various cancers using our products will have favorable results, whether awareness of our products in the medical community will continue or increase, future demand for IsoRay's existing and planned products, whether regulatory approvals and licenses will be obtained or maintained in foreign countries, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether additional studies will be published with favorable outcomes from treatment with our products, whether IsoRay's sales and marketing and research and development efforts will contribute to growth, whether new products will be developed and if so whether they will be adopted by physicians, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of IsoRay's products, changing levels of demand for IsoRay's current and proposed future products, IsoRay's ability to reduce or maintain expenses while increasing sales, whether additional studies are released and support the conclusions of past studies, patient results achieved with our products, successful completion of future research and development activities, our ability of our distributors and customers to receive and maintain all required regulatory approvals in the U.S. and internationally, continued compliance with ISO standards as audited by BSI, the success of our sales and marketing efforts, IsoRay's ability to successfully manufacture, market and sell its products, whether institutions will receive all required state, federal and foreign regulatory approvals and licenses to use IsoRay's products, IsoRay's ability to manufacture its products in sufficient quantities to meet demand within required delivery time periods while meeting its quality control standards, IsoRay's ability to enforce its intellectual property rights, changes in reimbursement rates, changes in laws and regulations applicable to our products, and other risks detailed from time to time in IsoRay's reports filed with the SEC.
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
Dec. 9, 2016 10:30 AM EST Reads: 2,090
Dec. 9, 2016 10:15 AM EST Reads: 420
Dec. 9, 2016 10:15 AM EST Reads: 1,924
Dec. 9, 2016 10:15 AM EST Reads: 1,980
Dec. 9, 2016 10:13 AM EST Reads: 153
Dec. 9, 2016 08:45 AM EST Reads: 983
Dec. 9, 2016 08:30 AM EST Reads: 2,229
Dec. 9, 2016 08:30 AM EST Reads: 1,139
Dec. 9, 2016 08:00 AM EST Reads: 999
Dec. 9, 2016 07:45 AM EST Reads: 1,213
Dec. 9, 2016 07:00 AM EST Reads: 4,363
Dec. 9, 2016 06:00 AM EST Reads: 839
Dec. 9, 2016 05:00 AM EST Reads: 3,164
Dec. 9, 2016 04:45 AM EST Reads: 526
Dec. 9, 2016 04:30 AM EST Reads: 1,051